Figure 7.
Schematic overview of the workflow for selecting an HLA-A*0201 MAGE-A10254-262-specific TCR candidate to progress to comprehensive pre-clinical testing.
The number of TCRs under investigation at each stage and the types of experimental procedures involved in progressing candidates from one stage to the next are shown. This resulted in two mutant TCRs with desirable functional properties that were indistinguishable by previously described assays. The X-scan approach identified c796 as the TCR with the highest potency and specificity.